Form 8-K

8-K — AbbVie Inc.

Accession: 0001104659-26-076067

Filed: 2026-06-22

Period: 2026-06-18

CIK: 0001551152

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2618365d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2618365d1_ex99-1.htm)

EX-99.2 — EXHIBIT 99.2 (tm2618365d1_ex99-2.htm)

GRAPHIC (tm2618365d1_ex99-1img001.jpg)

GRAPHIC (tm2618365d1_ex99-2img001.jpg)

GRAPHIC (tm2618365d1_ex99-2img002.jpg)

GRAPHIC (tm2618365d1_ex99-2img003.jpg)

GRAPHIC (tm2618365d1_ex99-2img004.jpg)

GRAPHIC (tm2618365d1_ex99-2img005.jpg)

GRAPHIC (tm2618365d1_ex99-2img006.jpg)

GRAPHIC (tm2618365d1_ex99-2img007.jpg)

GRAPHIC (tm2618365d1_ex99-2img008.jpg)

GRAPHIC (tm2618365d1_ex99-2img009.jpg)

GRAPHIC (tm2618365d1_ex99-2img010.jpg)

GRAPHIC (tm2618365d1_ex99-2img011.jpg)

GRAPHIC (tm2618365d1_ex99-2img012.jpg)

GRAPHIC (tm2618365d1_ex99-2img013.jpg)

GRAPHIC (tm2618365d1_ex99-2img014.jpg)

GRAPHIC (tm2618365d1_ex99-2img015.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2618365d1_8k.htm · Sequence: 1

false

0001551152

2026-06-18

0001551152

us-gaap:CommonStockMember

exch:XNYS

2026-06-18

0001551152

abbv:SeniorNotes0.750Percentdue2027Member

exch:XNYS

2026-06-18

0001551152

abbv:SeniorNotes2.125Percentdue2028Member

exch:XNYS

2026-06-18

0001551152

abbv:SeniorNotes2.625Percentdue2028Member

exch:XNYS

2026-06-18

0001551152

abbv:SeniorNotes2.125Percentdue2029Member

exch:XNYS

2026-06-18

0001551152

abbv:SeniorNotes1.250Percentdue2031Member

exch:XNYS

2026-06-18

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to

Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date of Report (Date of earliest event

reported): June 18, 2026

ABBVIE

INC.

(Exact name of registrant as specified in its charter)

Delaware

001-35565

32-0375147

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

North Waukegan Road

North

Chicago, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

Registrant’s

telephone number, including area code: (847) 932-7900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, $0.01 Par Value

ABBV

New

York Stock Exchange

NYSE Texas

0.750%

Senior Notes due 2027

ABBV27

New

York Stock Exchange

2.125%

Senior Notes due 2028

ABBV28

New

York Stock Exchange

2.625%

Senior Notes due 2028

ABBV28B

New

York Stock Exchange

2.125%

Senior Notes due 2029

ABBV29

New

York Stock Exchange

1.250%

Senior Notes due 2031

ABBV31

New

York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD Disclosure

On June 22, 2026, AbbVie Inc. (the “Company”) and Apogee

Therapeutics, Inc. (“Apogee”) issued a joint press release announcing a definitive agreement pursuant to which the Company

will acquire Apogee, on the terms and subject to the conditions set forth therein. The press release is attached hereto as Exhibit 99.1

and incorporated by reference herein.

On June 22, 2026, representatives of the Company will present information

about the proposed transaction to various investors of the Company. The presentation will include the slides attached hereto as Exhibit

99.2 and incorporated by reference herein.

The information in this Item 7.01, including the exhibits referenced

herein and attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934

(the “Exchange Act”), nor shall they be deemed incorporated by reference in any Company filing under the Securities Act of

1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Forward-Looking Statements

This Current Report on Form 8-K (including the exhibits thereto) contains

statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act

of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. All statements

other than statements of historical fact, including statements regarding market and industry prospects and future results of operations

or financial position made in this Current Report on Form 8-K are forward-looking. In many cases, you can identify forward-looking statements

by terminology, such as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,”

“believes,” “estimates,” “predicts,” “potential,” “continue” or the negative

of such terms and other comparable terminology. Statements in this Current Report on Form 8-K that are forward-looking may include, but

are not limited to, statements regarding the benefits of the proposed acquisition of Apogee by AbbVie and the associated integration plans,

anticipated future operating performance and results of Apogee, the expected accretion to Abbvie’s adjusted diluted earnings per

share beginning in 2032, the expected timing of the closing of the proposed acquisition and other transactions contemplated by the merger

agreement governing the proposed acquisition (the “Merger Agreement”), and the potential of zumilokibart (APG777) and other

Apogee’s pipeline assets. There may also be other statements of expectations, beliefs, future plans and strategies, anticipated

events or trends and similar expressions concerning matters that are not historical facts. Readers are cautioned that any such forward-looking

statements are not guarantees of future performance and involve risks and uncertainties, many of which are difficult to predict and are

generally outside Apogee’s control, that could cause actual performance or results to differ materially from those expressed in,

or implied or projected by, the forward-looking statements. Such risks and uncertainties include, but are not limited to: the occurrence

of any event, change or other circumstance that could give rise to the right of Apogee or AbbVie or both of them to terminate the Merger

Agreement, including circumstances requiring a party to pay the other party a termination fee pursuant to the Merger Agreement; the failure

to obtain applicable regulatory or Apogee stockholder approval in a timely manner or otherwise; the risk that the proposed acquisition

may not close in the anticipated timeframe or at all due to one or more of the other closing conditions to the transaction not being satisfied

or waived; the possibility of competing acquisition proposals for Apogee; the risk that there may be unexpected costs, charges or expenses

resulting from the proposed acquisition; risks related to the ability of Apogee and AbbVie to successfully integrate the businesses and

the possibility that such integration may be more difficult, time consuming or costly than expected; risks that the proposed transaction

disrupts Apogee’s or AbbVie’s current plans and operations; the risk that certain restrictions during the pendency of the

proposed transaction may impact Apogee’s ability to pursue certain business opportunities or strategic transactions; risks related

to disruption of each company’s management’s time and attention from ongoing business operations due to the proposed transaction;

the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Apogee’s

and/or AbbVie’s common stock, credit ratings or operating results; the risk that the proposed transaction and its announcement could

have an adverse effect on the ability of Apogee and AbbVie to retain and hire key personnel, to retain customers and to maintain relationships

with each of their respective business partners, suppliers and customers and on their respective operating results and businesses generally;

the risk of litigation that could be instituted against the parties to the Merger Agreement or their respective directors, managers or

officers and/or regulatory actions related to the proposed acquisition, including the effects of any outcomes related thereto; the risk

that zumilokibart (APG777) or APG273 and other Apogee’s pipeline assets may not demonstrate the anticipated success, safety, or

efficacy in ongoing or future clinical trials; the risk that positive Phase 2 and Phase 1b interim results for zumilokibart (APG777) may

not be predictive of results in later-stage or larger clinical trials; challenges to intellectual property; adverse litigation or government

action; competition from other products; difficulties inherent in the research and development process; risks related to unpredictable

and severe or catastrophic events, including but not limited to acts of terrorism, war or hostilities, cyber attacks, or the impact of

any pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide on Apogee’s or AbbVie’s business,

financial condition and results of operations, as well as the response thereto by each company’s management; and other business

effects, including the effects of industry, market, economic, political or regulatory conditions. Also, Abbvie’s and Apogee’s

actual results may differ materially from those contemplated by the forward-looking statements for a number of additional reasons as described

in Abbvie’s and Apogee’s filings with the Securities and Exchange Commission (the “SEC”), including those set

forth in the Risk Factors section and under any “Forward-Looking Statements” or similar heading in Abbvie’s and Apogee’s

most recently filed Annual Report on Form 10-K filed on February 20, 2026 and March 2, 2026, respectively, and subsequent Quarterly Reports

on Form 10-Q and Current Reports on Form 8-K. Abbvie and Apogee have based these forward-looking statements on their current expectations

and projections about future events. Although the parties believe that the assumptions on which the forward-looking statements contained

herein are based are reasonable, any of those assumptions could prove to be inaccurate. As a result, the forward-looking statements based

upon those assumptions also could be incorrect. Except to the extent required by law, Abbvie and Apogee undertake no obligation to publicly

update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.

Exhibit

99.1

Press Release, dated June 22, 2026, jointly issued by AbbVie Inc. and Apogee Therapeutics, Inc.

99.2

Investor Presentation

104

The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBVIE INC.

Date:

June 22, 2026

By:

/s/ Scott T. Reents

Scott T. Reents

Executive Vice President, Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2618365d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

AbbVie

to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

· Proposed

acquisition adds a diverse pipeline of assets focused on elevating the standard of care for

patients with dermatologic, respiratory and other related inflammatory and immunological

diseases

· Apogee's

lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients

with atopic dermatitis

· Apogee’s

pipeline also includes combinations of its novel antibodies; APG273, a potential best-in-category

long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), is being

developed in asthma

· Apogee

shareholders to receive $135.11 per share in cash, for a total equity value of approximately

$10.9 billion

· AbbVie

to hold investor conference call today, June 22, at 8:00 a.m. CT

NORTH

CHICAGO, Ill., SAN FRANCISCO and BOSTON, June 22, 2026 – AbbVie (NYSE: ABBV) and Apogee Therapeutics (NASDAQ: APGE) (“Apogee”)

today announced they have entered into a definitive agreement under which AbbVie will acquire Apogee and its diverse pipeline of multiple

clinical-stage candidates in development across inflammatory and immunological diseases, including atopic dermatitis (AD) and asthma.

The acquisition complements AbbVie's existing immunology portfolio and accelerates AbbVie’s clinical presence in the respiratory

space.

Under

the terms of the transaction, AbbVie will acquire all outstanding shares of Apogee for $135.11 per share in cash. The transaction values

Apogee at a total equity value of approximately $10.9 billion. The boards of directors of both companies have unanimously approved the

transaction. This transaction is expected to close in the third quarter of 2026, subject to customary closing conditions, including Apogee

shareholder approval and receipt of regulatory approvals.

“For

more than two decades, AbbVie has led and shaped the field of immunology bringing the science, scale and expertise needed to address

some of the most complex diseases,” said Robert A. Michael, Chairman and Chief Executive Officer, AbbVie. “The acquisition

of Apogee further builds on our existing leadership, strengthening our ability to deliver innovative medicines to patients who need

better options while also creating significant long-term value for shareholders. Apogee’s pipeline adds highly differentiated clinical-stage

assets, further expanding our robust immunology portfolio in areas of significant patient need, including atopic dermatitis and asthma.

With our deep scientific expertise and proven capabilities, we are uniquely positioned to rapidly advance these programs and continue

to transform the standard of care in inflammatory diseases.”

This

acquisition holds potential for substantial shareholder value creation with mega-blockbuster peak sales potential across Apogee’s

pipeline of assets, including its lead asset, zumilokibart (APG777), a subcutaneous half-life extended monoclonal antibody targeting

IL-13, being developed in AD and APG273, a combination of zumilokibart and APG333, an anti-TSLP half-life extended monoclonal antibody,

being developed in asthma.

“This

transaction reflects the strength of Apogee’s vision, our team’s dedication, and the significant progress we’ve made

advancing zumilokibart and our differentiated pipeline,” said Michael Henderson, M.D., chief executive officer, Apogee. “Since

our founding, we’ve focused on developing transformative therapies for patients with inflammatory diseases while creating value

for shareholders. This transaction delivers substantial shareholder value and positions our programs to reach their full potential. We

are deeply grateful to the patients, physicians and investigators who helped make this milestone possible. We believe AbbVie can advance

zumilokibart and our portfolio while expanding their impact for patients worldwide.”

Zumilokibart

targets IL-13, a critical cytokine in type 2 inflammation, and a central driver of inflammatory diseases like AD and asthma. Specifically

in AD, a large majority of patients do not achieve simultaneous itch and skin improvement which represents an opportunity for the development

of novel treatments that not only provide better skin clearance and itch resolution but also improve convenience with less frequent dosing.

In its Phase 2 clinical trial, zumilokibart attained clinically significant results, with approximately two-thirds of patients on treatment

achieving significant skin clearance at 16 weeks, along with notable improvements in itch reduction and overall disease control. These

findings support its potential best-in-category profile, including strong efficacy and significantly improved dosing, in patients with

AD. Longer-term data from the same trial also supports highly convenient maintenance regimens of either quarterly or twice a year dosing.

The safety profile of zumilokibart is favorable and consistent with other medicines in its class, and the molecule has the potential

to be evaluated in several additional inflammatory indications.

Beyond

zumilokibart, Apogee has built a broader pipeline of novel antibodies targeting multiple validated inflammatory pathways. APG273 combines

zumilokibart with APG333, an antibody that blocks TSLP, a signaling protein that acts as an early trigger of inflammation in the lungs.

Phase 1 data showed that APG333 has a long half-life and was able to suppress relevant type 2 inflammatory markers for up to six months

after dosing. The Phase 1 data with APG333 and positive interim results from a phase 1b study of zumilokibart in asthma, supports the

potential of the APG273 combination with quarterly or twice-yearly injections in asthma.

Transaction

Terms

Under the terms of the definitive agreement, AbbVie will acquire all

outstanding Apogee common stock for $135.11 per share in cash. The proposed transaction is subject to customary closing conditions,

including receipt of regulatory approvals and approval by Apogee shareholders. Fairmount Funds Management LLC and Venrock Associates

have entered into voting agreements in support of the transaction.

The

proposed transaction is expected to be accretive to AbbVie’s adjusted diluted earnings per share (EPS) beginning in 2032.

AbbVie

Conference Call Details

AbbVie

will host an investor conference call today, June 22, at 8:00 a.m. CT to discuss this transaction. The call will be webcast

through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the call will be available after 9:00

a.m. CT. Presentation materials for the investor conference call are available here.

Advisors

AbbVie's

financial advisor is Morgan Stanley & Co. LLC and Paul, Weiss, Rifkind, Wharton & Garrison LLP is serving as legal advisor.

Apogee’s

financial advisors are Jefferies LLC and Goldman Sachs & Co. LLC, and Kirkland & Ellis LLP is serving as legal advisor.

About

AbbVie in Immunology

AbbVie

is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping

them live a life free from the limitations of their disease. For more than 20 years, AbbVie has led and helped shape the field of immunology

through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology,

and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities,

novel mechanisms of actions and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.

Today,

more than 1 million patients worldwide are treated with AbbVie’s immunology medicines, approved in more than 175 countries across

19 immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next

wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more

information, please visit www.abbvie.com/immunology.

About

AbbVie

AbbVie's

mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical

challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology,

neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie,

please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

About

Apogee Therapeutics

Apogee

Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing

in the largest I&I markets, including for the treatment of AD, asthma, EoE, Chronic Obstructive Pulmonary Disease (COPD) and other

I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established

mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart, the company’s

most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I

markets, as well as asthma and EoE. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy

and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company

believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information,

please visit https://apogeetherapeutics.com.

Cautionary

Statement Regarding Forward-Looking Statements

This

communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities

Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each

as amended. All statements other than statements of historical fact, including statements regarding market and industry prospects and

future results of operations or financial position made in this communication are forward-looking. In many cases, you can identify forward-looking

statements by terminology, such as “may,” “should,” “expects,” “intends,” “plans,”

“anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue”

or the negative of such terms and other comparable terminology. Statements in this communication that are forward-looking may include,

but are not limited to, statements regarding the benefits of the proposed acquisition of Apogee Therapeutics, Inc. (“Apogee”)

by AbbVie Inc. (“AbbVie”) and the associated integration plans, anticipated future operating performance and results of Apogee,

the expected accretion to AbbVie’s adjusted diluted earnings per share beginning in 2032, the expected timing of the closing of

the proposed acquisition and other transactions contemplated by the merger agreement governing the proposed acquisition (the “Merger

Agreement”), and the potential of zumilokibart (APG777) and other Apogee’s pipeline assets.

There

may also be other statements of expectations, beliefs, future plans and strategies, anticipated events or trends and similar expressions

concerning matters that are not historical facts. Readers are cautioned that any such forward-looking statements are not guarantees of

future performance and involve risks and uncertainties, many of which are difficult to predict and are generally outside Apogee’s

control, that could cause actual performance or results to differ materially from those expressed in, or implied or projected by, the

forward-looking statements. Such risks and uncertainties include, but are not limited to: the occurrence of any event, change or other

circumstance that could give rise to the right of Apogee or AbbVie or both of them to terminate the Merger Agreement, including circumstances

requiring a party to pay the other party a termination fee pursuant to the Merger Agreement; the failure to obtain applicable regulatory

or Apogee stockholder approval in a timely manner or otherwise; the risk that the proposed acquisition may not close in the anticipated

timeframe or at all due to one or more of the other closing conditions to the transaction not being satisfied or waived; the possibility

of competing acquisition proposals for Apogee; the risk that there may be unexpected costs, charges or expenses resulting from the proposed

acquisition; risks related to the ability of Apogee and AbbVie to successfully integrate the businesses and the possibility that such

integration may be more difficult, time consuming or costly than expected; risks that the proposed transaction disrupts Apogee’s

or AbbVie’s current plans and operations; the risk that certain restrictions during the pendency of the proposed transaction may

impact Apogee’s ability to pursue certain business opportunities or strategic transactions; risks related to disruption of each

company’s management’s time and attention from ongoing business operations due to the proposed transaction; the risk that

any announcements relating to the proposed transaction could have adverse effects on the market price of Apogee’s and/or AbbVie’s

common stock, credit ratings or operating results; the risk that the proposed transaction and its announcement could have an adverse

effect on the ability of Apogee and AbbVie to retain and hire key personnel, to retain customers and to maintain relationships with each

of their respective business partners, suppliers and customers and on their respective operating results and businesses generally; the

risk of litigation that could be instituted against the parties to the Merger Agreement or their respective directors, managers or officers

and/or regulatory actions related to the proposed acquisition, including the effects of any outcomes related thereto; the risk that zumilokibart

(APG777) or APG273 and other Apogee’s pipeline assets may not demonstrate the anticipated success, safety, or efficacy in ongoing

or future clinical trials; the risk that positive Phase 2 and Phase 1b interim results for zumilokibart (APG777) may not be predictive

of results in later-stage or larger clinical trials; challenges to intellectual property; adverse litigation or government action; competition

from other products; difficulties inherent in the research and development process; risks related to unpredictable and severe or catastrophic

events, including but not limited to acts of terrorism, war or hostilities, cyber attacks, or the impact of any pandemic, epidemic or

outbreak of an infectious disease in the United States or worldwide on Apogee’s or AbbVie’s business, financial condition

and results of operations, as well as the response thereto by each company’s management; and other business effects, including

the effects of industry, market, economic, political or regulatory conditions.

Also, AbbVie’s and Apogee’s actual

results may differ materially from those contemplated by the forward-looking statements for a number of additional reasons as described

in AbbVie’s and Apogee’s filings with the Securities and Exchange Commission (the “SEC”), including those set

forth in the Risk Factors section and under any “Forward-Looking Statements” or similar heading in AbbVie’s and Apogee’s

most recently filed Annual Report on Form 10-K filed on February 20, 2026 and March 2, 2026, respectively, and subsequent Quarterly Reports

on Form 10-Q and Current Reports on Form 8-K.

AbbVie and Apogee have based these forward-looking

statements on their current expectations and projections about future events. Although the parties believe that the assumptions on which

the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate. As a

result, the forward-looking statements based upon those assumptions also could be incorrect. Except to the extent required by law, AbbVie

and Apogee undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information,

future events or otherwise.

Additional

Information and Where to Find It

This

communication is being made in respect of the proposed transaction involving Apogee and AbbVie. A meeting of the stockholders of Apogee

will be announced as promptly as practicable to seek Apogee stockholder approval in connection with the proposed transaction. Apogee

intends to file relevant materials with the SEC, including preliminary and definitive proxy statements relating to the proposed transaction.

The definitive proxy statement will be mailed to Apogee’s stockholders. This communication is not a substitute for the proxy statement

or any other document that may be filed by Apogee with the SEC.

BEFORE

MAKING ANY DECISION, APOGEE STOCKHOLDERS ARE URGED TO CAREFULLY READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS (INCLUDING ANY AMENDMENTS

OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION

OR INCORPORATED BY REFERENCE INTO THE PROXY STATEMENT WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT

THE PROPOSED TRANSACTION.

Any

vote in respect of resolutions to be proposed at Apogee’s stockholder meeting to approve the proposed transaction or other responses

in relation to the proposed transaction should be made only on the basis of the information contained in Apogee’s proxy statement.

You will be able to obtain a free copy of the proxy statement and other related documents (when available) filed by Apogee with the SEC

at the website maintained by the SEC at www.sec.gov or by accessing the Investors section of Apogee’s website at https://investors.apogeetherapeutics.com.

Offer or Solicitation

This

communication is for informational purposes only and is not intended to, and does not constitute or form part of, an offer,

invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of

any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise,

nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

Participants

in the Solicitation

Apogee, AbbVie and their respective directors and executive officers

and certain of their employees may be deemed to be participants in the solicitation of proxies from Apogee’s stockholders in connection

with the proposed transaction. Information regarding Apogee’s directors and executive officers is set forth under the captions

“Proposal 1: Election of Directors,” “Corporate Governance,” “Executive Officers,” “Executive

Compensation” and “Certain Information About Our Common Stock” in the definitive proxy statement for Apogee’s

2026 Annual Meeting of Stockholders, filed with the SEC on April

24, 2026, and in Apogee’s Current Reports on Form 8-K, filed with the SEC on April

24, 2026 and June 12, 2026.

Information regarding AbbVie’s directors and executive officers is set forth under the captions “Information Concerning Director

Nominees,” “The Board of Directors and its Committees,” “Director Compensation,” “Securities Ownership”

and “Executive Compensation” in the definitive proxy statement for AbbVie’s 2026 Annual Meeting of Stockholders, filed

with the SEC on March 23,

2026, and in AbbVie’s Current Report on Form 8-K, filed with the SEC on May

12, 2026. To the extent holdings of Apogee’s securities and AbbVie’s securities by their respective directors or executive

officers have changed since the amounts set forth in such filings, such changes have been or will be reflected on Initial Statements

of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4 filed with the SEC. These documents may be obtained

free of charge from the SEC’s website at www.sec.gov or by accessing the Investors section of Apogee’s website at

https://investors.apogeetherapeutics.com and the Investors section of AbbVie’s website at https://investors.abbvie.com.

Additional information regarding the interests of participants in the solicitation of proxies in connection with the proposed transaction

will be included in the proxy statement that Apogee expects to file in connection with the proposed transaction and other relevant materials

Apogee may file with the SEC.

###

AbbVie

Contacts

Media:

Marianne

Ostrogorski

marianne.ostrogorski@abbvie.com

Investors:

Liz

Shea

liz.shea@abbvie.com

Apogee

Contacts

Media:

Andi

Rose / Aura Reinhard

Investors:

Noel

Kurdi

Joele

Frank, Wilkinson Brimmer Katcher

(212)

355-4449

VP,

Investor Relations

noel.kurdi@apogeetherapeutics.com

Dan

Budwick

1AB

Media

dan@1abmedia.com

EX-99.2 — EXHIBIT 99.2

EX-99.2

Filename: tm2618365d1_ex99-2.htm · Sequence: 3

Exhibit 99.2

Acquisition of Apogee Therapeutics

June 22, 2026

June 22, 2026 2

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of

1934, each as amended. All statements other than statements of historical fact, including statements regarding market and industry prospects and future results of operations or financial position made in this communication are forward-looking. In many

cases, you can identify forward-looking statements by terminology, such as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of such terms and other comparable terminology.

Statements in this communication that are forward-looking may include, but are not limited to, statements regarding the benefits of the proposed acquisition of Apogee Therapeutics, Inc. (“Apogee”) by AbbVie Inc. (“AbbVie”) and the associated integration

plans, anticipated future operating performance and results of Apogee, the expected accretion to Abbvie’s adjusted diluted earnings per share beginning in 2032, the expected timing of the closing of the proposed acquisition and other transactions

contemplated by the merger agreement governing the proposed acquisition (the “Merger Agreement”), and the potential of zumilokibart (APG777) and other Apogee’s pipeline assets.

There may also be other statements of expectations, beliefs, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. Readers are cautioned that any such forward-looking statements

are not guarantees of future performance and involve risks and uncertainties, many of which are difficult to predict and are generally outside Apogee’s control, that could cause actual performance or results to differ materially from those expressed in, or

implied or projected by, the forward-looking statements. Such risks and uncertainties include, but are not limited to: the occurrence of any event, change or other circumstance that could give rise to the right of Apogee or AbbVie or both of them to terminate

the Merger Agreement, including circumstances requiring a party to pay the other party a termination fee pursuant to the Merger Agreement; the failure to obtain applicable regulatory or Apogee stockholder approval in a timely manner or otherwise; the risk

that the proposed acquisition may not close in the anticipated timeframe or at all due to one or more of the other closing conditions to the transaction not being satisfied or waived; the possibility of competing acquisition proposals for Apogee; the risk that

there may be unexpected costs, charges or expenses resulting from the proposed acquisition; risks related to the ability of Apogee and AbbVie to successfully integrate the businesses and the possibility that such integration may be more difficult, time

consuming or costly than expected; risks that the proposed transaction disrupts Apogee’s or AbbVie’s current plans and operations; the risk that certain restrictions during the pendency of the proposed transaction may impact Apogee’s ability to pursue

certain business opportunities or strategic transactions; risks related to disruption of each company’s management’s time and attention from ongoing business operations due to the proposed transaction; the risk that any announcements relating to the

proposed transaction could have adverse effects on the market price of Apogee’s and/or AbbVie’s common stock, credit ratings or operating results; the risk that the proposed transaction and its announcement could have an adverse effect on the ability of

Apogee and AbbVie to retain and hire key personnel, to retain customers and to maintain relationships with each of their respective business partners, suppliers and customers and on their respective operating results and businesses generally; the risk of

litigation that could be instituted against the parties to the Merger Agreement or their respective directors, managers or officers and/or regulatory actions related to the proposed acquisition, including the effects of any outcomes related thereto; the risk that

zumilokibart (APG777) or APG273 and other Apogee’s pipeline assets may not demonstrate the anticipated success, safety, or efficacy in ongoing or future clinical trials; the risk that positive Phase 2 and Phase 1b interim results for zumilokibart (APG777)

may not be predictive of results in later-stage or larger clinical trials; challenges to intellectual property; adverse litigation or government action; competition from other products; difficulties inherent in the research and development process; risks related to

unpredictable and severe or catastrophic events, including but not limited to acts of terrorism, war or hostilities, cyber attacks, or the impact of any pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide on Apogee’s or

AbbVie’s business, financial condition and results of operations, as well as the response thereto by each company’s management; and other business effects, including the effects of industry, market, economic, political or regulatory conditions.

Also, Abbvie’s and Apogee’s actual results may differ materially from those contemplated by the forward-looking statements for a number of additional reasons as described in Abbvie’s and Apogee’s filings with the Securities and Exchange Commission (the

“SEC”), including those set forth in the Risk Factors section and under any “Forward-Looking Statements” or similar heading in Abbvie’s and Apogee’s most recently filed Annual Report on Form 10-K filed on February 20, 2026 and March 2, 2026,

respectively, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Abbvie and Apogee have based these forward-looking statements on their current expectations and projections about future events. Although the parties believe that the assumptions on which the forward-looking statements contained herein are based are

reasonable, any of those assumptions could prove to be inaccurate. As a result, the forward-looking statements based upon those assumptions also could be incorrect. Except to the extent required by law, Abbvie and Apogee undertake no obligation to

publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This presentation contains certain non-GAAP financial measures. Non-GAAP financial measures are adjusted for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses and other specified items

presented in AbbVie’s reconciliation tables. AbbVie’s management believes non-GAAP financial measures provide useful information to investors regarding AbbVie’s results of operations and assist management, analysts and investors in evaluating the

performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. AbbVie does not provide a reconciliation of forward-looking

non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, certain acquisition-related expenses, gains and losses from equity securities, actuarial gains and losses from pension and postretirement plan remeasurements, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain,

depend on various factors and could have a material impact on GAAP reported results for the guidance period.

This presentation is intended for the investor community only; materials are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions.

Forward-Looking Statements and Non-GAAP Financial Information

June 22, 2026 3

Strong Strategic Fit for AbbVie

Leverages AbbVie’s regulatory and clinical expertise,

commercial capabilities and international infrastructure to

maximize Apogee’s high-value assets

Complements AbbVie’s Immunology pipeline by adding

multiple potentially differentiated assets to treat

inflammatory diseases

Potential for substantial shareholder value creation with

mega-blockbuster peak sales potential across Apogee’s

pipeline of assets

June 22, 2026 4

Apogee Overview

Clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy

and dosing for the treatment of atopic dermatitis, asthma and other inflammatory conditions

• Portfolio of long-acting antibodies targeting well-established biological drivers in immunology

• Potential to treat numerous inflammatory conditions

• Potential to achieve improved efficacy and dosing through

monotherapies and combinations of novel antibodies

• Lead asset, zumilokibart, demonstrated potentially best-in-category efficacy and favorable safety with Q12W and Q24W

dosing in Ph2 atopic dermatitis study

• Zumilokibart expected to significantly improve dosing

frequency compared to existing biologics, potentially

requiring fewer than half the number of injection days

• Zumilokibart expansion potential in dermatology and

respiratory as a monotherapy or coformulation with APG333

(half-life extended anti-TSLP antibody)

June 22, 2026 5

Apogee Well-Aligned With AbbVie Strategic Goals in Immunology

ELEVATE CARE OFFER CONVENIENCE DEVELOP CURES

Rinvoq

AA, Vitiligo, HS, SLE

Lutikizumab

Skyrizi SubQ Induction in IBD B-cell Depletion in Rheumatology

Oral Peptides for PsO, PsA & IBD

Novel Combinations in Dermatology

IL23 / IL1/ / Amylin

Novel Combinations in Gastroenterology

IL23 / 47 / TL1A / TREM1 / JAK / LPAR1

Novel Combinations in Rheumatology

IL23 / TL1A / IL1/ / CD40 / TREM1 / JAK / LPAR1

Bispecific Antibodies

Longer-Acting Antibodies

Zumilokibart Monotherapy in Atopic Dermatitis & Other Inflammatory Conditions

APG273 (Zumilokibart + APG333) in Asthma & COPD

1 2 3

AA: alopecia areata, COPD: chronic obstructive pulmonary disease, HS: hidradenitis suppurativa, IBD: inflammatory bowel disease,

PsA: psoriatic arthritis, PsO: psoriasis, SLE: systemic lupus erythematosus

Pipeline Focused

on Next-Generation

Medicines to Elevate

Standard of Care

Broad Immune

Modulating Effect

EVOLUTION OF

ABBVIE IMMUNOLOGY

INNOVATION

Increased

Specificity,

Efficacy and/or

Convenience

June 22, 2026 6

Apogee Highly Complementary to AbbVie’s Immunology Pipeline

Phase 1 Phase 2 Phase 3

Under Regulatory

Review

ABBVIE IMMUNOLOGY

PROGRAMS

ABBV-313 (IL13/IL31R) Ph1 start Q3 2026

ABBV-142 (LPAR1)

IPF

Lutikizumab (IL1)

Rinvoq (JAKi)

Alopecia Areata

ABBV-319 (CD19 ADC)

SLE, SjD

ABBV-8736 (TREM1)

Rinvoq (JAKi)

Vitiligo

ABBV-519 (CD19)

RA, SLE

Lutikizumab (IL1) + Ravagalimab (CD40)

Rinvoq (JAKi)

SLE

Skyrizi Subcutaneous Induction

ABBV-547 (Long-Acting IL23)

PsO

Skyrizi (IL23) + ABBV-382 (47)

CD, UC Ph2b start Q3 2026

ABBV-619 (CD19 CAR-T)

RA, SLE

Skyrizi (IL23) + ABBV-701 (TL1A)

CD, UC Ph2b start Q3 2026

ABBV-722 (LPAR1i)

IPF

Skyrizi (IL23) + Lutikizumab (IL1)

PsA

ABBV-722 (LPAR1i) + Rinvoq (JAKi)

RA, SSc

ABBV-848 (IRAK4i)

ABBV-859 (IL23Ri) Ph1 start Q3 2026

PsO

ABBV-1451 (IL1)

APOGEE PROGRAMS

Zumilokibart (IL13) Atopic Dermatitis (Positive Part B 16-week data) Ph3 start 2H26

Zumilokibart Asthma (Positive Ph1b data)

Zumilokibart Eosinophilic Esophagitis Ph2a start 2H26

APG273 (IL13 + TSLP) Asthma / COPD Clinical trial plans to be announced 2H26

AD: atopic dermatitis, CD: Crohn’s disease, COPD: chronic obstructive pulmonary disease, HS: hidradenitis suppurativa, IPF: idiopathic pulmonary fibrosis, PsA: psoriatic arthritis, PsO:

psoriasis, RA: rheumatoid arthritis, SjD: Sjögren's disease, SLE: systemic lupus erythematosus, SSc: systemic sclerosis, UC: ulcerative colitis

June 22, 2026 7

Atopic Dermatitis

• ~$18 billion global revenues

growing more than 15% annually

• ~2.5x more moderate-to-severe

patients than psoriasis

• ~8% penetration for advanced

therapies

• Only ~20% of patients simultaneously

achieve itch and skin improvement

(NRS 0/1 & EASI90) on today’s best

therapies

• Opportunities for novel treatments

that provide improved convenience or

better skin clearance / itch resolution

• AD is frequently comorbid with other

T2-mediated diseases

• ~25% of AD patients also have asthma

• ~40% of AD patients have allergic

rhinitis, including chronic rhinosinusitis

with nasal polyps

Transaction unlocks a more comprehensive portfolio of therapies for AD patients

• Zumilokibart as potential early-line option offering best-in-category efficacy and dosing

• Rinvoq as a highly effective oral option for patients not adequately controlled with other systemic drug products, including biologics

High Overlap With Other

Inflammatory Conditions

High Unmet

Need

Large and Growing

Atopic Dermatitis

Therapeutic Area

Source: Evaluate Pharma, AbbVie internal estimates, Rinvoq Phase 3 Level-Up data, PMID: 32112994, PMID: 33684526

June 22, 2026 8

Zumilokibart (APG777)

Extended Half-life Anti-IL13 Antibody Being Developed as a Monotherapy or Combination

Therapy in Dermatology, Respiratory and Other Immune-Mediated Diseases

• Across a robust, reproducible two-part Ph2 study, zumilokibart

demonstrated strong lesion and itch control that improved over time

• Delivered numerically higher absolute response rates and placebo-adjusted efficacy across key endpoints compared to currently marketed

AD biologics

• Well tolerated with a safety profile similar to other biologics

• Ph3 AD trials expected to begin 2H 2026; Potential approval early 2030

• Expansion potential in dermatology and respiratory indications as a

monotherapy and coformulation

Potential for Best-in-Category Efficacy in AD

• Sustained efficacy with every 3-month and 6-month dosing intervals

out to a year of follow up

• Extended half-life enables 4 dosing days for induction and 2-4 dosing

days per year for maintenance

• Expected to require ~½ the number of injection days compared to

Ebglyss and ~¼ the number of injection days compared to Dupixent

in first year of treatment

• Market research supports Q12W-Q24W dosing as a meaningful

market value driver in atopic dermatitis, supporting potential for

strong share capture

Potential for Substantially Lower Injection Burden

• Monotherapy: Eosinophilic Esophagitis (EoE), Chronic Pruritus of Unknown Origin (CPUO), Chronic Spontaneous Urticaria (CSU), Prurigo Nodularis (PN)

• Combination Therapy: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

• Indications planned for zumilokibart mono or combo therapies represents collective addressable market of ~$40 billion today1

Potential Indication Expansion to Inflammatory Conditions Where IL13 Plays a Critical Role

1Evaluate Pharma

June 22, 2026 9

Zumilokibart (APG777) Atopic Dermatitis Phase 2 APEX Part B

Numerically Higher Absolute Response Rates and Placebo-Adjusted Efficacy Across Key

Endpoints Compared to Currently Marketed AD Biologics

23%

17% 14%

30%

43%

38%

34%

14%

Zumi Ebglyss Dupixent Nemluvio

EASI 75 Responders at 16 Weeks

X% PBO-adjusted

PBO response

X% Treatment response

9% 9% 8%

18%

38%

26% 27% 8%

Zumi Ebglyss Dupixent Nemluvio

EASI 90 Responders at 16 Weeks

66%

55%

48%

44%

14% 12% 11%

18%

37%

30% 28%

24%

Zumi Ebglyss Dupixent Nemluvio

I-NRS ≥4 Reduction from Baseline at 16 Weeks

47%

35% 35%

26%

51%

42%

39%

42%

+TCS +TCS +TCS

EASI 75: Eczema Area and Severity Index (EASI) percent score reduction of at least 75, EASI 90: Eczema Area and Severity Index (EASI) percent score reduction of at least 90, I-NRS ≥4: proportion of

participants achieving a ≥4 point improvement from baseline in weekly mean of the daily itch numeric rating scale.

Note: The data presented above are not from a head-to-head study. Efficacy data are derived from different clinical trials conducted at different times, with differences in trial design and patient

populations. As a result, cross-trial comparisons cannot be made, and no head-to-head clinical trials have been conducted. The data were derived from zumilokibart mid dose from Phase 2 APEX

Part B study (dose selected for Phase 3 program), lebrikizumab Phase 3 Advocate 1 & 2 studies, dupilumab Phase 3 SOLO 1 & 2 studies, nemolizumab plus topical corticosteroids (TCS) Phase 3

ARCADIA 1 & 2 studies. Zumilokibart has not been approved in AD and its safety and efficacy in this indication has not been evaluated by regulatory agencies.

June 22, 2026 10

Zumilokibart (APG777) Atopic Dermatitis Phase 2 APEX Part A

Zumilokibart 360mg Q24W

Zumilokibart 360mg Q12W

Continuous

Improvement Across

All Endpoints Through

Week 52

Zumilokibart 360mg Q24W

Zumilokibart 360mg Q12W

Zumilokibart 16-Week Induction

Durable Maintenance

of Responses with

Both Q12W and Q24W

Dosing

Source: Apogee Corporate Presentation

All subjects who were initially randomized to zumilokibart induction were assessed through 52 weeks.

Phase 3 monotherapy studies will evaluate exposure-matched maintenance dosing regimens of 360mg Q12W and 720mg Q24W

Source: Apogee Corporate Presentation

Subjects who achieved a response at week 16 were assessed for maintenance of response through week 52.

Phase 3 monotherapy studies will evaluate exposure-matched maintenance dosing regimens of 360mg Q12W and 720mg Q24W.

June 22, 2026 11

Asthma Represents a Large and Underserved Market

Opportunity to Grow Market with Commercial Investment and Innovation

Significant Opportunity in Asthma Market

Treatment Options for

Type 2 Low Asthma

Elevated Efficacy in

Type 2 High Asthma

Improved

Adherence

• Ongoing exacerbations, steroid dependence,

and symptom breakthroughs despite current

biologics

• Need for more reliable exacerbation reduction,

and more meaningful improvements in lung

function and quality of life

• Sizable population (10% - 40%) of Type 2

Low patients, for whom current biologics

offer limited efficacy

• Demand exists for novel, broader

phenotype-agnostic treatments

• Current leading biologics dosed Q2W – Q8W

• Strong need for longer-interval dosing

(Q12W+) to reduce treatment burden and

improve patient compliance

~7 million severe,

uncontrolled patients

~9% penetration

rate for advanced

therapies in global

severe market

~$18 billion global

asthma market

growing more than

15% annually

High Unmet Need for Novel Treatments

Source: Evaluate Pharma, AbbVie internal estimates, PMID: 32586877

June 22, 2026 12

APG273 (Zumilokibart + APG333)

Dual IL13 / TSLP Inhibition Could Provide Transformational Efficacy for Type 2 High and Low

Asthma Patients with Significantly Improved Q12W Dosing

• Dual blockage of two clinically validated asthma disease pathways (IL13 / TSLP) has potential for enhanced efficacy

• Zumilokibart demonstrated durable FeNO suppression and FEV1 improvement in Ph1b asthma study

• APG333 demonstrated tezepelumab-like inhibition of T2 biomarkers in Ph1 healthy volunteers

• Preclinical data show zumilokibart + APG333 combination has a broader effect on both central and local drivers of obstructive airway disease compared to

tezepelumab, dupilumab and lebrikizumab

Strong Rationale for IL13 / TSLP Combination in Asthma

Source: Apogee Corporate Presentation. Note: Data not from head-to-head clinical studies, see Apogee presentation for full disclaimer. FeNO: fractional exhaled nitric oxide,

FEV1: forced expiratory volume in 1 second.

Zumilokibart Phase 1b Asthma Data

Single Dose Demonstrated Durable FeNO Suppression Through 32-Weeks / Achieved Competitive FeNO Reduction

June 22, 2026 13

Transaction and Financial Overview

• AbbVie has agreed to acquire all outstanding shares of Apogee for a purchase price of $135.11 per share in an all-cash transaction

• Premium of approximately 49% to the closing price on June 18, 2026

• Purchase price of $10.9B; Implied transaction value of approximately $10.1B net of estimated cash and marketable securities acquired1

• Will fund the transaction with debt

PURCHASE

PRICE

• Apogee’s pipeline assets represent mega-blockbuster collective peak sales potential

• Zumilokibart in atopic dermatitis represents most substantial component of the deal value

• Modest value ascribed to APG273 given early stage of development

DEAL

VALUE

CAPITAL

ALLOCATION

PRIORITIES

FINANCIAL

IMPACT

• Closing expected third quarter of 2026, subject to Apogee shareholder approval, regulatory approvals and other customary closing conditions

• Expected to negatively impact adjusted diluted EPS by approximately $0.14 in 2026 (partial year) and approximately $0.46 in 2027

• Expect adjusted diluted earnings per share accretion beginning in 2032 and significantly ramping over the long term

• No change to AbbVie’s capital allocation priorities

• Remain committed to a strong and growing dividend; continue to have financial flexibility for additional business development

• Expect to maintain A2/A- credit rating; Committed to achieving net leverage ratio of 2x within 2-3 years of deal closing

1Net cash and marketable securities position acquired includes impact of the buy-back option for change of control under the Apogee revenue share agreement with Blackstone Life

Sciences to reduce a significant portion of the expected future royalty obligation for zumilokibart.

June 22, 2026 14

Key Takeaways

A strong strategic fit for AbbVie that represents an attractive opportunity to acquire a pipeline of

potentially differentiated assets focused on treating inflammatory conditions

• Complements AbbVie’s Immunology pipeline by adding a portfolio of long-acting, high-efficacy assets targeting

dermatology, respiratory and other immune-mediated diseases

• Provides AbbVie with a late-stage atopic dermatitis asset, zumilokibart, that has the potential to provide best-in-category

efficacy, safety comparable to approved biologics and significantly more convenient Q12W – Q24W dosing

• Enables AbbVie to enter large and underserved respiratory markets, such as asthma and COPD

Potential to create substantial shareholder value

• Apogee’s pipeline assets represent mega-blockbuster collective peak sales potential

• Assets represent potential new sources of growth to support AbbVie’s performance in the 2030’s and beyond

• AbbVie will leverage its regulatory and clinical expertise, commercial capabilities, and international infrastructure in

Immunology to maximize Apogee’s high-value assets

GRAPHIC

Filename: tm2618365d1_ex99-1img001.jpg · Sequence: 8

Binary file (2222 bytes)

Download tm2618365d1_ex99-1img001.jpg

GRAPHIC

Filename: tm2618365d1_ex99-2img001.jpg · Sequence: 9

Binary file (37083 bytes)

Download tm2618365d1_ex99-2img001.jpg

GRAPHIC

Filename: tm2618365d1_ex99-2img002.jpg · Sequence: 10

Binary file (426202 bytes)

Download tm2618365d1_ex99-2img002.jpg

GRAPHIC

Filename: tm2618365d1_ex99-2img003.jpg · Sequence: 11

Binary file (112318 bytes)

Download tm2618365d1_ex99-2img003.jpg

GRAPHIC

Filename: tm2618365d1_ex99-2img004.jpg · Sequence: 12

Binary file (159857 bytes)

Download tm2618365d1_ex99-2img004.jpg

GRAPHIC

Filename: tm2618365d1_ex99-2img005.jpg · Sequence: 13

Binary file (147940 bytes)

Download tm2618365d1_ex99-2img005.jpg

GRAPHIC

Filename: tm2618365d1_ex99-2img006.jpg · Sequence: 14

Binary file (124209 bytes)

Download tm2618365d1_ex99-2img006.jpg

GRAPHIC

Filename: tm2618365d1_ex99-2img007.jpg · Sequence: 15

Binary file (137685 bytes)

Download tm2618365d1_ex99-2img007.jpg

GRAPHIC

Filename: tm2618365d1_ex99-2img008.jpg · Sequence: 16

Binary file (215219 bytes)

Download tm2618365d1_ex99-2img008.jpg

GRAPHIC

Filename: tm2618365d1_ex99-2img009.jpg · Sequence: 17

Binary file (180333 bytes)

Download tm2618365d1_ex99-2img009.jpg

GRAPHIC

Filename: tm2618365d1_ex99-2img010.jpg · Sequence: 18

Binary file (154371 bytes)

Download tm2618365d1_ex99-2img010.jpg

GRAPHIC

Filename: tm2618365d1_ex99-2img011.jpg · Sequence: 19

Binary file (154570 bytes)

Download tm2618365d1_ex99-2img011.jpg

GRAPHIC

Filename: tm2618365d1_ex99-2img012.jpg · Sequence: 20

Binary file (180852 bytes)

Download tm2618365d1_ex99-2img012.jpg

GRAPHIC

Filename: tm2618365d1_ex99-2img013.jpg · Sequence: 21

Binary file (180145 bytes)

Download tm2618365d1_ex99-2img013.jpg

GRAPHIC

Filename: tm2618365d1_ex99-2img014.jpg · Sequence: 22

Binary file (179898 bytes)

Download tm2618365d1_ex99-2img014.jpg

GRAPHIC

Filename: tm2618365d1_ex99-2img015.jpg · Sequence: 23

Binary file (19527 bytes)

Download tm2618365d1_ex99-2img015.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 25

v3.26.1

Cover

Jun. 18, 2026

Entity Listings [Line Items]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 18, 2026

Entity File Number

001-35565

Entity Registrant Name

ABBVIE

INC.

Entity Central Index Key

0001551152

Entity Tax Identification Number

32-0375147

Entity Incorporation, State or Country Code

Entity Address, Address Line One

North Waukegan Road

Entity Address, City or Town

North

Chicago

Entity Address, State or Province

Entity Address, Postal Zip Code

60064-6400

City Area Code

847

Local Phone Number

932-7900

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Common Stock [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]

Entity Listings [Line Items]

Title of 12(b) Security

Common

Stock, $0.01 Par Value

Trading Symbol

ABBV

Security Exchange Name

NYSE

Senior Notes 0. 750 Percentdue 2027 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]

Entity Listings [Line Items]

Title of 12(b) Security

0.750%

Senior Notes due 2027

Trading Symbol

ABBV27

Security Exchange Name

NYSE

Senior Notes 2. 125 Percentdue 2028 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]

Entity Listings [Line Items]

Title of 12(b) Security

2.125%

Senior Notes due 2028

Trading Symbol

ABBV28

Security Exchange Name

NYSE

Senior Notes 2. 625 Percentdue 2028 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]

Entity Listings [Line Items]

Title of 12(b) Security

2.625%

Senior Notes due 2028

Trading Symbol

ABBV28B

Security Exchange Name

NYSE

Senior Notes 2. 125 Percentdue 2029 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]

Entity Listings [Line Items]

Title of 12(b) Security

2.125%

Senior Notes due 2029

Trading Symbol

ABBV29

Security Exchange Name

NYSE

Senior Notes 1. 250 Percentdue 2031 [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]

Entity Listings [Line Items]

Title of 12(b) Security

1.250%

Senior Notes due 2031

Trading Symbol

ABBV31

Security Exchange Name

NYSE

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_EntityListingsLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

dei_EntityListingsExchangeAxis=exch_XNYS

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes0.750Percentdue2027Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes2.125Percentdue2028Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes2.625Percentdue2028Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes2.125Percentdue2029Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=abbv_SeniorNotes1.250Percentdue2031Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type: